116 related articles for article (PubMed ID: 7794084)
1. The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs.
Bauer JH; Reams GP
Arch Intern Med; 1995 Jul; 155(13):1361-8. PubMed ID: 7794084
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
Ohlstein EH; Brooks DP; Feuerstein GZ; Ruffolo RR
Pharmacology; 1997 Nov; 55(5):244-51. PubMed ID: 9399334
[TBL] [Abstract][Full Text] [Related]
3. [Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology].
Winkler G; Jermendy G; Matos L
Orv Hetil; 2003 Sep; 144(36):1763-8. PubMed ID: 14579673
[TBL] [Abstract][Full Text] [Related]
4. Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
Ramahi TM
Postgrad Med; 2001 Apr; 109(4):115-22; quiz 9. PubMed ID: 11317462
[TBL] [Abstract][Full Text] [Related]
5. [Irbesartan: a new possibility in the treatment of hypertension].
Rapi J
Orv Hetil; 2002 May; 143(21):1187-92. PubMed ID: 12073539
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?
Grossman E; Messerli FH; Neutel JM
Arch Intern Med; 2000 Jul; 160(13):1905-11. PubMed ID: 10888965
[No Abstract] [Full Text] [Related]
7. Angiotensin-II receptor antagonists: their place in therapy.
Kirk JK
Am Fam Physician; 1999 Jun; 59(11):3140-8. PubMed ID: 10392595
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan.
Shetty SS; DelGrande D
J Pharmacol Exp Ther; 2000 Jul; 294(1):179-86. PubMed ID: 10871310
[TBL] [Abstract][Full Text] [Related]
9. [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Sidorenko BA; Preobrazhenskiĭ DV; Soplevenko AV; Ivanova NA; Stetsenko TM
Kardiologiia; 2004; 44(1):55-65. PubMed ID: 15029149
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
[TBL] [Abstract][Full Text] [Related]
11. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Schmidt B; Schieffer B
J Med Chem; 2003 Jun; 46(12):2261-70. PubMed ID: 12773029
[No Abstract] [Full Text] [Related]
13. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
Siegl PK; Chang RS; Mantlo NB; Chakravarty PK; Ondeyka DL; Greenlee WJ; Patchett AA; Sweet CS; Lotti VJ
J Pharmacol Exp Ther; 1992 Jul; 262(1):139-44. PubMed ID: 1625193
[TBL] [Abstract][Full Text] [Related]
14. The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism.
Ohlstein EH; Gellai M; Brooks DP; Vickery L; Jugus J; Sulpizio A; Ruffolo RR; Weinstock J; Edwards RM
J Pharmacol Exp Ther; 1992 Aug; 262(2):595-601. PubMed ID: 1501114
[TBL] [Abstract][Full Text] [Related]
15. Cardiology patient page. Angiotensin receptor blockers.
Terra SG
Circulation; 2003 Jun; 107(24):e215-6. PubMed ID: 12821593
[No Abstract] [Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.
Csajka C; Buclin T; Brunner HR; Biollaz J
Clin Pharmacokinet; 1997 Jan; 32(1):1-29. PubMed ID: 9012554
[TBL] [Abstract][Full Text] [Related]
17. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes.
Edwards RM; Trizna W; Stack EJ; Weinstock J
J Pharmacol Exp Ther; 1996 Jan; 276(1):125-9. PubMed ID: 8558420
[TBL] [Abstract][Full Text] [Related]
18. Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial.
Kyvelou SM; Vyssoulis GP; Karpanou EA; Adamopoulos DN; Zervoudaki AI; Pietri PG; Stefanadis CI
Hellenic J Cardiol; 2006; 47(1):21-8. PubMed ID: 16532712
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data].
Paoletti V; Di Veroli C; Pugliese M; Cammarella I; Cavina G; Turchetti P; Mammarella A
Clin Ter; 2002; 153(1):61-4. PubMed ID: 11963637
[TBL] [Abstract][Full Text] [Related]
20. Pathologic consequences of increased angiotensin II activity.
Ferrario CM; Flack JM
Cardiovasc Drugs Ther; 1996 Nov; 10(5):511-8. PubMed ID: 8950064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
